⌕
Xenon Pharmaceuticals · XENE · Nasdaq
Tenet 44 · Weak
Compare
$38.78−1.22%At closeTenet 44 · Weak
$38.78−0.48 (−1.22%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Xenon Pharmaceuticals (XENE) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is XENE's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Zacks Investment ResearchNov 17, 2026 · 12:16 ET
Xenon Stock Rises 12% in the Past Month on Pipeline Progress

XENE's shares jump 12% as azetukalner advances, pain candidates deliver encouraging results and a strong cash position supports pipeline growth.…

XENE −1.2% todayRead at source ↗
● Seeking AlphaNov 9, 2026 · 22:40 ET
Xenon Pharmaceuticals Inc. (XENE) Q3 2026 Earnings Call Transcript

Xenon Pharmaceuticals Inc. (XENE) Q3 2026 Earnings Call Transcript…

XENE −1.2% todayRead at source ↗
● MarketBeatNov 9, 2026 · 22:15 ET
Xenon Pharmaceuticals Q3 Earnings Call Highlights

Xenon Pharmaceuticals NASDAQ: XENE expects pivotal depression study results in December, earlier than previously projected, while preparing for a potential U.S. launch of its lead epilepsy drug and advancing two pain tre…

XENE −1.2% todayRead at source ↗
● GlobeNewsWireNov 9, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Xenon Reports Q3 2026 Financial Results and Provides Business Update

New Drug Application for azetukalner in focal seizures submitted to U.S. Food & Drug Administration in September 2026 Expanding potential opportunity in epilepsy through ongoing Phase 3 X-TOLE3 and X-ACKT studies and pla…

XENE −1.2% todayRead at source ↗
● GlobeNewsWireNov 3, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Xenon to Present at Upcoming Investor Conferences

VANCOUVER, BC and BOSTON, MA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercia…

XENE −1.2% todayRead at source ↗
● GlobeNewsWireNov 2, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Xenon to Report Q3 2026 Financial Results on November 9, 2026

VANCOUVER, BC and BOSTON, MA, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercia…

XENE −1.2% todayRead at source ↗
● GlobeNewsWireOct 30, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, BC and BOSTON, MA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercia…

XENE −1.2% todayRead at source ↗
● GlobeNewsWireOct 29, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain

XEN1701 achieved target profile, including desired Na V 1.7 receptor occupancy in both the peripheral and central nervous system, and was generally well-tolerated with no notable autonomic cardiovascular effects XEN1120 …

XENE −1.2% todayRead at source ↗
● GlobeNewsWireOct 20, 2026 · 20:50 ET
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is continuing its investigation into potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).…

XENE −1.2% todayRead at source ↗
● Zacks Investment ResearchOct 15, 2026 · 14:06 ET
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?

Xenon pauses enrollment in late-stage depression trials after unexpected side effects, while its epilepsy pipeline offers growth potential.…

XENE −1.2% todayRead at source ↗
● GlobeNewsWireOct 7, 2026 · 10:30 ET
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors

NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP continues to investigate potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).…

XENE −1.2% todayRead at source ↗
● GlobeNewsWireOct 2, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, BC and BOSTON, MA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercia…

XENE −1.2% todayRead at source ↗
● MarketBeatSep 27, 2026 · 12:02 ET
Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review

Xenon Pharmaceuticals NASDAQ: XENE said it has filed its first new drug application for azetukalner as a treatment for focal-onset seizures, while pausing portions of its late-stage psychiatry program to evaluate changes…

XENE −1.2% todayRead at source ↗
● Business WireSep 23, 2026 · 00:23 ET
XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $XENE--XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law.…

XENE −1.2% todayRead at source ↗
● PRNewsWireSep 22, 2026 · 18:18 ET
Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)

Analysts cut price targets and reduced their estimates for azetukalner's psychiatric commercial opportunity after Xenon Pharmaceuticals disclosed an enrollment pause in its Phase 3 depression trials -- XENE shares fell a…

XENE −1.2% todayRead at source ↗
● Seeking AlphaSep 22, 2026 · 08:14 ET
Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate

Azetukalner's focal-seizure application gives Xenon Pharmaceuticals Inc. a potential path to its first commercial revenues, subject to FDA approval. The psychiatry setback weakens expansion potential, but I think epileps…

XENE −1.2% todayRead at source ↗
● GlobeNewsWireSep 22, 2026 · 07:47 ET
Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).…

XENE −1.2% todayRead at source ↗
● GlobeNewsWireSep 21, 2026 · 16:01 ET
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercia…

XENE −1.2% todayRead at source ↗
● Proactive InvestorsSep 18, 2026 · 12:24 ET
Xenon Pharmaceuticals falls 30% after depression trial enrollment pause

Xenon Pharmaceuticals Inc. (XENE:NASDAQ) shares were down 30%, on Friday morning after the company voluntarily halted new enrollment in major depressive disorder and bipolar depression studies. The events were consistent…

XENE −1.2% todayRead at source ↗
● Zacks Investment ResearchSep 18, 2026 · 12:10 ET
XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback

Xenon files an FDA application for azetukalner in epilepsy as its depression studies face a temporary enrollment pause.…

XENE −1.2% todayRead at source ↗
● BenzingaSep 18, 2026 · 11:14 ET
Xenon Stock Reaction Is Overblown: Analyst

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) submitted a New Drug Application to the U.S. Food and Drug Administration for its investigational drug azetukalner to treat focal seizures.…

XENE −1.2% todayRead at source ↗
● BenzingaSep 18, 2026 · 08:01 ET
Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday's Pre-Market Session

U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining around 150 points on Friday.…

XENE −1.2% todayRead at source ↗
● BarronsSep 18, 2026 · 07:32 ET
Xenon Stock Faces Worst Day Since 2017 as Lead Drug Proves a Double-Edged Sword

Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar depression following ‘adverse events.'…

XENE −1.2% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just XENE · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.